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Abstract
Introduction: Patients who are lost to follow-up (LTFU) while on antiretroviral therapy (ART) pose challenges to the
long-term success of ART programs. We describe the extent to which patients considered LTFU are misclassified as
true disengagement from care when they are still alive on ART and explain reasons for ART discontinuation using
our active tracing program to further improve ART retention programs and policies.
Methods: We identified adult ART patients who missed clinic appointment by more than 3 weeks between January
2006 and December 2010, assuming that such patients would miss their doses of antiretroviral drugs. Patients
considered LTFU who consented during ART registration were traced by phone or home visits; true ART status after
tracing was documented. Reasons for ART discontinuation were also recorded for those who stopped ART.
Results: Of the 4,560 suspected LTFU cases, 1,384 (30%) could not be traced. Of the 3,176 successfully traced
patients, 952 (30%) were dead and 2,224 (70%) were alive, of which 2,183 (99.5%) started ART according to phone-
based self-reports or physical verification during in-person interviews. Of those who started ART, 957 (44%) stopped
ART and 1,226 (56%) reported still taking ART at the time of interview by sourcing drugs from another clinic, using
alternative ART sources or making brief ART interruptions. Among 940 cases with reasons for ART discontinuations,
failure to remember (17%), too weak/sick (12%), travel (46%), and lack of transport to the clinic (16%) were
frequently cited; reasons differed by gender.
Conclusion: The LTFU category comprises sizeable proportions of patients still taking ART that may potentially bias
retention estimates and misdirect resources at the clinic and national levels if not properly accounted for. Clinics
should consider further decentralization efforts, increasing drug allocations for frequent travels, and improving
communication on patient transfers between clinics to increase retention and adherence.
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Introduction
As provision of antiretroviral therapy (ART) expands
throughout sub-Saharan Africa, the high rate of loss to follow-
up (LTFU) among ART patients challenges the long-term
success of ART programs. In sub-Saharan Africa, a substantial
number of HIV-infected individuals are lost both before [1] and
after ART initiation [2,3]. Among those considered LTFU, up to
40% of those traced are reported dead [4]. Adjusting mortality
estimates among patients LTFU is recognized as an important
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correction factor [5] [6]. However, true outcomes of patients
considered LTFU do not just include deaths, but may also
include those with undocumented transfers, uninterrupted
therapy due to antiretroviral drugs (ARVs) received from other
sources, and brief treatment discontinuations [7,8]. These
additional outcomes are poorly understood.
Although several studies explored reasons for ART
discontinuation other than death among LTFU patients in
resource-poor countries [9,10], most of these studies were
implemented with only small sample sizes and may therefore
not be representative [10,11], limiting their generalizability and
application to other patient populations or settings. Additional
studies using patient data from large, public, urban ART
programs may better aid understanding of the reasons for ART
discontinuation among ART patients, especially in urban areas.
In the current climate of increasing ART program costs and
decreasing donor funding, true rates of LTFU are even more
critical for program evaluation, accurately determining retention
in ART care and correctly forecasting usage of HIV-related
drugs and commodities.
In 2006, the Lighthouse Trust, the largest ART provider in
Malawi’s central region, which has treated more than 38,000
patients between opening in 2001 and present, designed and
implemented a Back–to–Care (B2C) program to improve long-
term retention on ART at its two urban clinics. The B2C
program identifies patients who missed their next scheduled
clinic appointment by more than 21 days; these patients are
traced and advised to return to the clinic for ART continuation.
As a follow-up to our previous papers that determined the
proportion of LTFU returned to care through our B2C active
tracing [7] and identified the patient characteristics associated
with successful tracing [12], we now describe the extent to
which patients considered LTFU are misclassified as true
disengagement from care when they are still alive on ART and
explore the reasons for ART discontinuation among those who
actually stop to further improve ART retention programs and
policies.
Methods
Study design, sites and population
We conducted a retrospective cohort study based on routine
data from a patient tracing program at Lighthouse Trust’s two
public ART clinics in urban Malawi, Lighthouse and Martin
Preuss Center (MPC). All confirmed LTFU patients were traced
by either phone or home visit. Lighthouse and MPC ART clinics
are located in Lilongwe, Malawi’s capital city. On average,
Lighthouse and MPC manage 8,300 and 11,200 patients a
month, respectively, using a real-time, point of care electronic
data system (EDS) from which the data for this study came
[13].
All HIV-infected individuals aged 15 years or older who
received ART at Lighthouse and MPC between January 2006
and December 2010 were eligible for inclusion in this study.
Data collection
As is routine practice at Lighthouse and MPC, during the
study period all HIV diagnosed individuals were registered in
the EDS and asked for consent at registration to be traced in
case of LTFU. HIV-infected adults were started on ART if their
CD4 count was equal to or below 250 cells/µl or they were in
WHO clinical stage 3 or 4 in accordance with Malawi National
ART guidelines during the study period [14]. During the study
period, one generic fixed dose combination of treatment
(stavudine, lamivudine, nevirapine) was used as first line
regimen. Routine return visits were scheduled monthly during
the first six months on ART and every two months thereafter if
no clinical complications occurred. At each ART visit,
adherence was assessed using pill counts and entered in the
EDS. The EDS electronically calculated the next scheduled
ART visit based on regimen, prescribed schedule, number of
tablets newly dispensed, and tablets remaining at present visit.
ART program outcomes (alive and on ART, stopped ART, or
transferred out) were updated in the EDS at each clinic visit.
Deaths were generally updated retrospectively after active
tracing.
Data collection for the B2C program was previously
described [7]. In brief, patients with any ARV drug dispensing
record (including ARV initiation) who missed their next
scheduled appointment and, presumably, would have run out
of ARVs by three weeks or more were identified using the EDS
and considered LTFU. A team of B2C tracers first verified the
LTFU list to rule out EDS data errors by cross-checking patient
paper files at the clinic. Then, those patients assumed LTFU
who consented during ART registration were first traced by
phone up to five phone attempts if a working number was
provided and/or then up to three home visit attempts if
residential information was provided. The reported ART status
after either tracing methods was recorded as: 1)dead;
2)transferred to another ART clinic (either ‘official transfer’ if the
transfer-out notes were available in the patient’s health
passport but not at the ART facility, or ‘self-transfer’ if the
patient arranged the transfer independently); 3) alive on ART
(with ‘treatment gaps’ if a patient took none or fewer than the
prescribed drugs before the interview date (a brief ART
interruption), or with ‘uninterrupted therapy’ if the patient was
still taking the correct dose of ARVs despite missing
appointments); 4) stopped ART (clinician order or self-
directed); 5) refused to be interviewed; 6) never started ART
although they collected drugs; and 7) LTFU (not traced or not
found). We defined a ‘LTFU case’ as a single episode of a
missed appointment; patients could appear on the confirmed
tracing list more than once during the study period.
For distance to the clinics, we used Euclidian distances in
kilometers (Km) between Lighthouse or MPC and patient
village or locations of residence determined from Google,
Earth.
Statistical analysis
Statistical analysis was conducted using STATA 12.0.
Descriptive statistics was used to explain baseline
characteristics of the study population presented. In the
analysis of the reasons for collecting ARVs from other sources,
we included patients who reported self-transfer to another ART
clinic, uninterrupted therapy, treatment gaps and those who
stopped taking ARV drugs by themselves. Patients who self-
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transferred to another ART clinic were included because their
experience provided insight into the challenges faced by ART
patients, although they successfully remained in care. Similarly,
patients who stopped ART provided insight on their
experiences before they stopped. Log-binomial regression was
used to compare categories of tracing outcomes with baseline
characteristics of patients considered LTFU. Tracing outcomes
were classified as 1) successfully traced or not traced; 2)
Patients who accessed ART from alternative sources or those
who did not; 3) Patients with uninterrupted therapy or those
who discontinued treatment. Successfully traced, accessing
ART from alternative sources and uninterrupted therapy were
hazard events. A level of significance of P ≤ 0.05 was used.
Ethical considerations
Consent for tracing was obtained during ART registration
according to routine clinic procedures. The study was approved
by The Malawi National Health Science Research Committee
in Lilongwe and the Ethics Advisory Group of the International
Union against Tuberculosis and Lung Disease in Paris, France.
The ethics committees waived the need for patient consent to
be involved in the study because the study used routine
programmatic data and did not include any personal identifiers.
Results
Characteristics of the study population
Between January 2006 and December 2010, 21,382 adult
HIV-infected individuals accessed ART at Lighthouse and MPC
clinics (Table 1). Of these, 12,384 (58%) were female. The
median age at ART start was 34 years (interquartile range (IQR
29-41)). A total of 5,865 patients (27%) started ART in WHO
clinical stage 1 or 2 with CD4 count ≤250 cells/µl, 11,677 (55%)
in stage 3 and 3,697 (17%) in stage 4. For 145 patients (1%),
the reason for starting ART was missing. Maximum and
median times of follow-up were 5.0 years and 1.2 years,
respectively.
Of all the 21,382 patients, 4,145 (19%) missed their next
scheduled clinic appointment by at least 21 days: 3,768 (91%)
missed an appointment once, 319 (8%) twice and 58 (1%) at
least three times. Median interval between the date the patient
missed their appointment and tracing was 1.1 months (IQR
1.0-2.0). Table 1 shows baseline characteristics of patients
who missed a scheduled clinic appointment. The majority of
these patients were aged between 25 and 34 years (54%), in
WHO stage 3 (43%) and lived at least 5km from their clinic
(52%). LTFU patients aged 35 years and above or in WHO
stage 4 were more likely to be successfully traced (Table 2).
Forty-seven percent of the LTFU patients were successfully
traced by phone.
Tracing outcomes
Figure 1 shows tracing outcomes for ART patients who ran
out of ARVs for at least 21 days between January 2006 and
December 2010 at Martin Preuss Centre and Lighthouse
clinics. Of the 4,560 suspected LTFU cases, 1,384 (30%) could
not be traced due to: incorrect/incomplete addresses or change
of residence (1,291 (93%)); residence outside the clinics’
catchment areas (46 (3%)); or human resource shortages at
either clinic (47 (4%)). Of the 3,176 successfully traced
patients, 952 (30%) were dead and 2,224 (70%) were alive.
Only 29 (1%) of the patients found alive refused to be
interviewed. Of the 2,195 cases interviewed 2,183 (99%) had
started ART according to phone-based self-reports or physical
verification of health book or remaining pills during in-person
interviews.
Of the 2,183 who had started ART, 1,226 (56%) reported still
taking ARVs at the time of interview. Of those still on treatment,
744 (61%) reported receiving ART at another clinic: 121 had
self-transferred and 623 had transferred officially but their clinic
records were inaccurate. The remaining 482 (39%) were still in
care at either Lighthouse or MPC clinics: 189 reported
uninterrupted therapy despite missing an appointment and 293
reported treatment gaps.
Access to and explanations for alternative ARV
sources
Among the 1,429 LTFU cases who reported self-transfer to
another ART clinic, self-stopped ARVs, uninterrupted therapy
or treatment gaps, we explored access to alternative sources of
ART during the period they were assumed to be LTFU. No
additional information was provided by 140 (10%) of patients.
Table 1. Baseline characteristics of patients considered lost
to follow-up from antiretroviral care at Lighthouse and
Martin Preuss Centre Clinics between January 2006 and
December 2010.
 Total (N=4,145) Lighthouse Martin Preuss Centre
Characteristics N (%) N (%) N(%)
Gender     
Male 1,908 (46%) 1,003 (47%) 905 (46%)
Female 2,237 (54% 1,153 (53%) 1,084 (54%)
Age at ART start     
15-24 529 (13%) 234 (11%) 295 (15%)
25-34 1,803 (43%) 865 (40%) 938 (47%)
35-44 1,171 (28%) 692 (32%) 479 (24%)
45+ 642 (15%) 365 (17%) 277 (14%)
Reason for starting ART¥     
CD4 ≤ 250 881 (22%) 383 (18%) 498 (25%)
WHO Stage 3 2,338 (57%) 1,202 (57%) 1,136 (58%)
WHO Stage 4 878 (21%) 539 (25%) 339 (17%)
Distance to the clinic£     
0-5km 1,865 (48%) 835 (41%) 1,030 (54%)
≥5km 2,048 (52%) 1,185 (59%) 863 (46%)
Year of ART start     
<2006 1,121 (27%) 1,054 (49%) 67 (3%)
2007 1,121 (27%) 434 (20%) 687 (35%)
2008 924 (22%) 361 (17%) 563 (28%)
2009-2010 979 (24%) 307 (14%) 672 (34%)
¥. 48 patients did not have information about reason for starting ART; £232
patients did not have information about distance to the clinic
doi: 10.1371/journal.pone.0075761.t001
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Of the remaining 1,289 patients, 311 (24%) collected ARVs
from alternative sources; 204 (65%) received ARVs from
another ARV clinic; 61 (20%) collected from drugs from other
sources such as unlicensed vendors and 46 (15%) received
ARVs from friends. Only 22 patients (7%) who collected ARVs
from other sources had completely stopped ART before the
time of interview. The most common reasons for collecting
ARVs from other sources were temporary change of residence
(65%), long waiting time/queues at the clinic (15%), moved to
other ARV clinic permanently (18%), and other reasons (25%)
(Figure 2). LTFU patients who started ART in 2007 and after
were less likely to access ART from alternative ART sources
(2007: RR=0.65 (95% CI 0.49-0.87); 2008: RR =0.65 (95%
0.48-0.90); 2009-2010: RR= 0.63 (95% CI 0.47-0.86)) (Table 2)
Table 2. Comparison of baseline characteristics by tracing
outcomes among patients considered lost to follow-up from
antiretroviral care at Lighthouse and Martin Preuss Centre











Characteristics RR¥ RR RR
Gender    
Female 1.00 1.00 1.00
Male 1.01 (0.97-1.05) 1.05 (0.84-1.31) 0.96 (0.77-1.19)
Age at ART start    
15-24 0.89 (0.82-0.96)** 0.64 (0.43-0.96) 0.54 (0.35-0.84)**
25-34 1.00 1.00 1.00
35-44 1.11(1.06-1.16)*** 1.17 (0.91-1.50) 1.16 (0.91-1.47)
45+ 1.13(1.07-1.19)*** 0.86 (0.59-1.24) 0.84 (0.58-1.21)
Reason for starting
ART    
CD4 ≤ 250 0.96 (0.91-1.01) 0.81 (0.61-1.08) 0.82 (0.62-1.09)
WHO Stage 3 1.00 1.00 1.00
WHO Stage 4 1.06(1.01-1.11)*** 1.08 (0.82-1.43) 1.01 (0.76-1.35)
Distance to the clinic    
< 5km 0.95 (0.91-0.99) 0.99 (0.79-1.24) 1.09 (0.88-1.36)
≥5km 1.00 1.00 1.00
Year of ART start    
<2006 1.00 1.00 1.00
2007 1.04 (0.99-1.10) 0.65(0.49-0.87)** 0.61 (0.46-0.81)**
2008 0.99 (0.93-1.05) 0.65(0.48-0.90)** 0.60 (0.44-0.83)**
2009-2010 1.01 (0.95-1.07) 0.63(0.47-0.86)** 0.62 (0.46-0.83)**
a Successfully traced vs not traced, b Patients who accessed alternative ARV
sources vs. those who did not, c Patients with uninterrupted therapy vs. those who
discontinued treatment. ¥ RR= Relative risk; *p < 0.05, **p < 0.01, ***p < 0.001
doi: 10.1371/journal.pone.0075761.t002
Reasons for ART discontinuation
Of those who started ART and were found alive, 957 (44%)
had stopped ART: 826 had stopped taking ART by themselves
and 131 were stopped by a clinician as documented in patient’s
health passport but not reflected in the electronic records. The
median interval between last clinic visit and stopping ART was
30 days (IQR 0-38). LTFU patients who started ART in 2007
and after were less likely to have uninterrupted therapy than
those starting before 2007 (2007: RR= 0.61 (95% CI
Figure 1.  Flowchart of tracing outcomes for ART patients
who run out of ARVs for at least 21 days between January
2006 and December 2010 at Martin Preuss Centre and
Lighthouse clinics in Lilongwe, Malawi.  LTFU = Lost to
follow-up; Official transfer’ if transfer-out notes were available
in the patient’s health book but not at the ART facility; or ‘self-
transfer’ if the patient arranged the transfer independently; a
patient could appear in more than one category during the
study period. ‘Treatment gaps’ if a patient took none or fewer
than the prescribed drugs before the interview date.
doi: 10.1371/journal.pone.0075761.g001
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0.46-0.81); 2008: RR =0.60 (95% CI 0.44-0.83); 2009-2010:
RR= 0.62 (0.46-0.83)).
All patients who were asked about alternative sources of
ARVs were also asked if they stopped treatment during the
considered LTFU period for any length of time. Of the 1,119
cases with treatment gaps and stopped ARVs, 179 (16%)
cases did not provide a reason for ART discontinuation. Among
the 940 cases with reasons, common explanations for
discontinuation of ARVs were failure to remember taking ARVs
[159 (17%)], feeling too weak/sick to go and collect ARVs [110
(12%)], travelling when ARVs ran out [431 (46%)] and lack of
money for transport to go to the clinic [152 (16%)] (Table 3).
Men were more likely than women to discontinue ART due to
travel (54% v 41%, p=0.001) while women were more likely to
report lack of money for transport compared to men (22% v
14%, p=0.013).
Discussion
This large study from two high-volume public urban ART
clinics found that 25% of patients suspected to be LTFU were
actually found alive and on ART when traced. Of those, 61%
had transferred to another ART clinic, 15% reported
uninterrupted therapy using ARVs from other sources and 24%
reported treatment gaps. About one fifth of traced patients
reported stopping ART. Although most patients had stopped by
themselves, some patients (3%) were stopped by a clinician
and had erroneous patient records. Among the 18% of traced
patients who stopped ART at some time, travel and financial
constraints were the primary causes of discontinuation. These
findings suggest both significant patient misclassification error
and an underestimation of overall ART program retention. Due
to the size of our patient population and the many years of
operation, our results likely reflect similar patient
misclassifications and ART program outcomes at the national
level. Using these results, we provide insight into interventions
for improving retention in ART clinics and suggest
improvements to estimating retention.
Figure 2.  Reasons for collecting ARVs from other ART
providers.  
doi: 10.1371/journal.pone.0075761.g002
First, our findings suggest that statistical methods to account
for mortality, treatment gaps and uninterrupted therapy among
patients classified as LTFU are needed. Approaches to correct
mortality [6] [4] and patients who self-transfer to another clinic
[15] for LTFU estimates exist; however, there are no methods
that approximate uninterrupted therapy and treatment gaps
among patients considered LTFU. As uninterrupted therapy
and treatment gaps comprise a sizeable proportion of those
identified as LTFU in our study, incorrectly accounting for these
outcomes may lead to underestimation of retention. For
example, out of a total of 391,300 patients alive on ART by 30
September 2012 in the Malawi National ART cohort,
approximately 90,000 patients were reported to be LTFU [16].
Applying the proportion of presumed LTFU found at Lighthouse
and MPC clinics to the national cohort data, almost 22,000
patients would be incorrectly categorized as disengagement of
care. Even if the proportion of patients who are true LTFU at
the Lighthouse and MPC clinics are slightly lower than the
national average, the incorrect classification of LTFU patients
as being completely off treatment may lead to inaccurate drug
forecasting and underestimation of drugs and commodities at
the national level. Considering the significant resource
constraints of most ART clinics in Malawi and in the region,
similar tracing programs of LTFU patients as part of routine
monitoring and evaluation using the B2C model are impractical.
However, using our findings to revise LTFU figures to reflect
numbers of patients with uninterrupted therapy or short-term
treatment interruptions may prove advantageous for program
Table 3. Reasons for discontinuing ART among patients
stopped ART or had treatment gaps at Lighthouse and







Non- respondents 179  70  109  
Respondents 940  856  184  
Forgotten to take ARVs 159 17% 93 11% 66 36%
Suspected side effects of
ARVs 43 5% 38 4% 5 3%
Very weak/sick 110 12% 91 11% 19 10%
Religious belief 65 7% 63 7% 2 1%
Travelled away 431 46% 363 42% 67 36%
Spouse did not approve
taking ARVs 5 1% 5 1% 0 0%
Transport costs 152 16% 135 16% 17 9%
The clinic was not helping 42 4% 41 5% 1 1%
Feeling healthy 10 1% 9 1% 1 1%
Not ready to take ARVs for
life 13 1% 13 2% 0 0%
Lack information about
ARVs 10 1% 6 1% 4 2%
Work responsibilities 27 3% 26 3% 1 1%
Other reasons 225 24% 199 23% 26 14%
*. Percentages are out of those who responded to each question; treatment gaps if
a patient took none or fewer than the prescribed drugs before the interview date.
doi: 10.1371/journal.pone.0075761.t003
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evaluation and forecasting. This recalculation becomes more
critical as increasing ART cohorts in Malawi and other high
burden countries will amplify this misclassification error and
result in program reporting bias.
Second, our study has implications for improvements at the
clinic level. We found that a substantial proportion of patients
initially considered LTFU were actually alive and collecting ART
from friends or other sources outside ART clinics, suggesting
the need for both clinic-based retention interventions and
improvements in data quality. One frequently cited reason for
collecting ART from friends or other sources was travel; this
reason was more frequently cited by men who often migrate for
work. Although patient travel is hard to predict, for patients who
inform clinic staff, increasing the number of pills prescribed per
visit to meet patient needs is advisable. In Malawi, national
policy notes that all documented ART patients may collect a
one-month, emergency supply of ARVs from any other ART
clinic – a policy specifically designed to help address patient
travel needs. However, clinicians and patients may not know
about this possibility, dramatically reducing the effectiveness of
this proactive policy. Educational efforts aimed at reminding
clinic staff and ART patients about this policy, recognition of
seasonal harvest periods which rely heavily on male labor, and
better documentation of policy application in patient health
passports are clearly needed to meet patient needs and
maintain accurate records. A greater challenge may be
presented by patients who collect drugs from friends, family or
other sources when they travel: their alternative-source ARVs
might be different from those prescribed at the ART clinic,
potentially reducing drug effectiveness, aiding the development
of side effects, or increasing potential for drug resistance.
Furthermore, waiting times and long queues were also noted
as a reason for missing appointments. Lighthouse and MPC
are the largest ARV providers in the central region of Malawi.
Almost 17% of ART patients in Lilongwe district access ART at
these two clinics, mainly because Lighthouse is a referral ART
clinic and MPC is located close to a transport hub easing travel
to clinic. In an internal study on clinic waiting times
(unpublished data), it was found that both clinics review around
600 patients a day and have patient waiting times that range
from 78 to 87 minutes per patient. Although this waiting time is
lower than the average waiting times reported by other similar
clinics [17] [18], Lighthouse and MPC are considering options
to further reduce waiting times by dispensing 2 to 3 months
drug refill periods for stable patients in order to minimise clinic
visits, scheduling visits over weekends, making time-specific
appointments for each patient in a day and providing ART in
the community through community based organisations. Lastly,
misclassifications also indicate issues in the data quality at
Lighthouse and MPC as well as highlight the need for ART
clinics to improve communication and transfers between sites.
Almost 23% of those successfully traced were accessing ART
from other clinics while being misclassified as LFTU at their
previous ART clinic. ART clinics need to establish data
linkages through which information of patients that transfer can
be shared.
Third, although significant proportions of patients considered
to be LTFU are dead or transferred to other clinics or are still
on ART, individual-level interventions are necessary to reduce
ART discontinuations as any treatment interruption could
increase the development of drug resistance, with both
individual- and population-level repercussions [19]. Decreasing
treatment interruptions requires specific, targeted interventions
that combine increased prevention of LTFU by providers with
improved responses to patient challenges. The most commonly
cited reasons for ART discontinuation are financial constraints
and travel, similar to findings from previous studies [20] [21].
These findings differ by gender; more men reporting travel
issues while more women reported financial constraints.
Patients who started ART in 2007 and after were less likely to
have uninterrupted therapy possibly because, by this time,
there were a number of ART clinics in the district. The findings
suggest that strategies for improving ART retention must take
into account the dual responsibilities of both providers and
patients and that interventions may need to differ by gender.
On the provider side, ART programs should further
decentralize ART clinics to reduce patient transport costs.
Although these efforts could benefit all patients, bringing ARVs
into the community may provide additional benefits for female
patients who may not control household finance and, therefore,
may encounter more problems securing money for travel costs
[22]. Additionally, as mentioned above, ART programs should
consider providing larger quantities of ARVs per visit for stable
patients to reduce the number of clinics visits, reducing
transport costs, decrease waiting times and better supply those
with unexpected travel. Lastly, a previous study noted patient
fear or concerns about provider reactions to their return to care
as reason for ART discontinuation [23]. Although not
specifically addressed in our study, additional efforts to
sensitize healthcare staff to be more welcoming when patients
return after missing or delaying appointments is critical to the
success of any intervention.
Our study should be considered with the following limitations.
First, we used routine program data collected from our patient
tracing program: some information was missing. Additional
reasons for patient discontinuation or treatment interruption
were not available, limiting the scope of the study. Moreover,
there may be differences in proportion of LTFU with
uninterrupted therapy and treatment gaps between patients
who are LTFU in urban ART clinics compared with those from
rural or private settings. Patients in rural ART clinics may have
lower mobility and fewer alternative sources of ART than their
urban peers. Moreover, self-reported data may reflect social
desirability bias so the true number of patients off treatment
may be higher. Despite these limitations, we believe that our
large sample size enables application of our findings to other
large urban clinics and makes our recommendations useful to
inform policy and the national ART program in Malawi and
other comparable settings.
Overall, although patients that are considered to be LTFU
comprise a sizeable proportion of true ART patient outcomes,
the category of LTFU includes a large proportion of patients
with uninterrupted therapy and treatment gaps that may bias
ART retention estimates at both the clinic and national levels.
While simultaneously making statistical adjustments to LTFU
estimates to account for actual treatment gaps and non-
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interrupted therapy, clinics and providers could potentially
expand clinic hours, increase ARV allocations for stable
patients, or work to further decentralize ARV distribution
locations to prevent LTFU. In combination, these policy and
program efforts could increase the accuracy of ART program
reporting and improve patient retention in care, making
significant contributions to improved management of ART
programs at the clinic and national levels.
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